You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

60 search results for: mechanism of disease

ERS 2024 | Pathophysiologic <b>Mechanism</b>s <b>of</b> Airway Remodeling in Severe Asthma

expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

14 min

Pulmonology

Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.

expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

35 min

Pulmonology

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, and discuss preclinical findings.

expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

14 min

Pulmonology

Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.

Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

interactivity

Understanding IL-33: A Key Factor in COPD Pathogenesis

5 min

Pulmonology

Explore the role of IL-33 in COPD pathophysiology and its potential as a therapeutic target

expert video

An Overview of Prurigo Nodularis

38 min

Dermatology

Dr. Raj Chovatiya highlights the clinical features, epidemiology, burden, diagnosis, and pathophysiology of prurigo nodularis.

Unique Characteristics <b>of</b> Itch in AD, PN, and CSU – A Panel Discussion

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

Podcast

ADVENT On Air | Expert Discussions in Dermatology

45 min

Dermatology

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

ADVENT On Air | Common Drivers <b>of</b> Type 2 Inflammatory <b>Disease</b>s

Podcast

ADVENT On Air | Common Drivers of Type 2 Inflammatory Diseases

15 min

Type 2 Inflammation

Profs. Klaus Rabe and Stephan Weidinger discuss shared and unique features of type 2 inflammatory diseases and the benefits of multidisciplinary care

interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

5 min

Dermatology

Mechanisms of itch in normal skin and the effect of type 2 inflammation on neurons leading in perpetuating itch in atopic dermatitis and prurigo nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region